CTOs on the Move

Forge Therapeutics Inc

www.forgetherapeutics.com

 
Forge Therapeutics is a biotechnology company developing novel medicines by combining bio-inorganic with medicinal chemistry to target metalloproteins. Forge has developed a fundamentally new approach for the discovery of metalloprotein inhibitors by focusing first on the metal in the enzyme active site.
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

Forge Therapeutics Inc raised $15M on 04/25/2017

Similar Companies

Promeddx

Promeddx is a Norton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Galecto

Galecto is a clinical stage biotechnology company committed to the development of novel small molecule therapeutics directed at biological targets which are at the heart of fibrosis, inflammation, and cancer. Galecto was founded by leading fibrosis-focused scientists and biotech executives and is built on more than 10 years of research into galectin and fibrosis modulators. Our team has developed a deep understanding of the galectin family of proteins and the LOXL2 enzyme, and how both influence multiple biological pathways of these complex, often devastating, diseases. Galecto is funded by Novo Holdings, OrbiMed, Ysios, HBM Healthcare Investments, Sunstone Capital, M Ventures, Bristol-Myers Squibb, Maverick Ventures, Seventure and SEED Capital.

Sengenics

Sengenics is a functional proteomics company that leverages its patented KREX technology to discover autoantibody biomarker signatures for prediction of drug response and severe immune-related adverse events (irAEs). KREX™ was invented and patented by Professor Jonathan Blackburn whilst he was a member of the faculty at the University of Cambridge. Jonathan is the CSO of Sengenics. The key application of KREX™ is the discovery of autoantibody biomarker signatures for prediction of drug response and severe immune-related adverse events (irAEs). KREX™ can also be used to identify autoantibody biomarkers that may be used to diagnose cancer, autoimmune or neurodegenerative conditions years before conventional diagnostic tests. Some autoantibodies that are identified as diagnostic biomarkers may be protective and have potential in themselves as therapeutic biomolecules.

Tevogen

Tevogen Bio brings together a highly skilled team of preeminent scientists, senior biopharmaceutical leaders, and manufacturing experts with the goal of advancing global health. The company`s patient centric mission is to leverage its proprietary cell and gene therapy platforms and novel business model to rapidly innovate breakthrough immunotherapies for cancers and viral infections with high unmet need. Tevogen Bio`s foundational vision is a healthier world through equitable access to lifesaving innovations.

Certus International Inc

Certus International Inc is a Bedford, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.